Lamisil · DIN 02031094 · 1% · Cr
General benefitMarketed · checked November 18, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
No interchangeable product listed in the Ontario extract
Lamisil · DIN 02031094
Manufacturer: Novartis Pharma Canada Inc.; listing date 1996-10-01
Health Canada: Marketed since 1999-02-23 · brand LAMISIL · ATC D01AE15 TERBINAFINE · form Cream · route Topical · ingredients TERBINAFINE HYDROCHLORIDE 1 %/% · company Cardinal health canada inc · schedule Prescription
Lamisil: Formulary list price $0.67 per unit (the source does not state the unit; exact figure $0.6727). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02031094)
Source record
DIN 02031094: Lamisil
Raw flags: sec3=Y
Item: 840408047; group id 824; item number 2009; lccId None; manufacturer id NOV
Source form: Cr; strength: 1%
Recorded listing: General benefit
Source prices (unrounded): $0.6727; ministry $0.6727
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02031094
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14532
Shortage status: not checked (no credentials)